domingo, 14 de febrero de 2021

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study - The Lancet Rheumatology

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study - The Lancet Rheumatology

No hay comentarios:

Publicar un comentario